newsfilter
← Earnings
Earnings Releases·

Heron Therapeutics — Third Quarter 2026 Earnings Summary

Heron Therapeutics reported third-quarter 2026 net revenue of $35.3 million, driven by a 13.8% increase in ZYNRELEF sales and a 49.3% rise in APONVIE sales, while oncology revenue declined due to the cessation of SUSTOL commercial sales. The company announced a definitive agreement for CorMedix Therapeutics to acquire substantially all of Heron's assets, a transaction pending stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents, having withdrawn its full-year 2026 financial guidance earlier in the year.

Company
HERON THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology